Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Vallance

Showing results (11-20 of 98) with videos related to

Pageof 10
Sort By:
Lancet (London, England)|February 1, 2003
Clinical and researchPatrick Vallance
BMJ (Clinical Research Ed.)|March 7, 2015
Patrick Vallance: Inquisitive and geekyPatrick Vallance
Lancet (London, England)|October 1, 2013
Secure use of individual patient data from clinical trialsPatrick Vallance, Iain Chalmers
Journal of the American Society of Nephrology : JASN|July 1, 2005
Asymmetric dimethylarginine and kidney disease--marker or mediator?Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology|April 24, 2004
Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathwayPatrick Vallance, James Leiper
Nature Reviews. Drug Discovery|December 4, 2002
Blocking NO synthesis: how, where and why?Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology|June 24, 2006
New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolaseJames Leiper, Patrick Vallance
British Journal of Pharmacology|January 13, 2006
The future of pharmacologyPatrick Vallance, Trevor G Smart
Circulation|January 5, 2005
Resolution for sepsis?Derek W Gilroy, Patrick Vallance
Current Pharmaceutical Design|July 20, 2005
Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disordersCaroline L Smith, Patrick Vallance
Pageof 10

Showing results (11-20 of 98) with videos related to

Sort By:
Pageof 10
Lancet (London, England)|February 1, 2003
Clinical and researchPatrick Vallance
BMJ (Clinical Research Ed.)|March 7, 2015
Patrick Vallance: Inquisitive and geekyPatrick Vallance
Lancet (London, England)|October 1, 2013
Secure use of individual patient data from clinical trialsPatrick Vallance, Iain Chalmers
Journal of the American Society of Nephrology : JASN|July 1, 2005
Asymmetric dimethylarginine and kidney disease--marker or mediator?Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology|April 24, 2004
Cardiovascular biology of the asymmetric dimethylarginine:dimethylarginine dimethylaminohydrolase pathwayPatrick Vallance, James Leiper
Nature Reviews. Drug Discovery|December 4, 2002
Blocking NO synthesis: how, where and why?Patrick Vallance, James Leiper
Arteriosclerosis, Thrombosis, and Vascular Biology|June 24, 2006
New tricks from an old dog: nitric oxide-independent effects of dimethylarginine dimethylaminohydrolaseJames Leiper, Patrick Vallance
British Journal of Pharmacology|January 13, 2006
The future of pharmacologyPatrick Vallance, Trevor G Smart
Circulation|January 5, 2005
Resolution for sepsis?Derek W Gilroy, Patrick Vallance
Current Pharmaceutical Design|July 20, 2005
Cardiovascular tests: use & limits of biochemical markers - therapeutic measurements of ADMA involved in cardiovascular disordersCaroline L Smith, Patrick Vallance
Pageof 10